Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Cited by papers we hold 4

• Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies · 2022
  No notice
• Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier · 2022
  No notice
• Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker · 2020
  No notice
• Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.